It's just that over the years I have seen examples of serious anticipatory selling ahead of what turned out to be a very positive trial result, and just the opposite, heavy buying ahead of a very negative result report.
In this case, I think the negatives resulting from the one-year delay in the oxypatch and the removal of POH from the ASX 300 are acting as an overall depressant - one which I hope will be dispelled by an oxymorphone performance that falls right into line with expectations, demonstrating that the company has the technology locked down.
so when is this news due?, page-36
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 40962233 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 39705430 | 30 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable